Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16
Open Access
- 4 May 2017
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
Abstract
Enhanced safety surveillance (ESS) was conducted in the United Kingdom and Finland for Vaxigrip and Intanza 15 µg to comply with the European Medicines Agency interim guidance aimed to detect any potential increase in reactogenicity in near real time following the annual update of the influenza vaccine strain composition. This pilot passive ESS was established to strengthen safety monitoring by facilitating spontaneous vaccinee reports and estimating near real-time vaccinee exposure. The primary objective was to estimate the reporting rates of suspected adverse reactions (ARs) occurring within 7 days post vaccination during the northern hemisphere 2015/16 influenza season. Among the Vaxigrip vaccinees (n = 1,012), 32 (3.2%) reported a total of 122 suspected ARs, including 110 suspected ARs that occurred within 7 days post vaccination. Among the Intanza 15 µg vaccinees (n = 1,017), 31 (3.0%) reported a total of 114 suspected ARs, including 99 that occurred within 7 days post-vaccination. These results were consistent with the known safety profile of the two vaccines and did not show any change in reactogenicity or safety concerns. This passive ESS showed improved data reporting and demonstrated its suitability to health authorities’ requirements; further fine tuning of the methodology is under discussion between all stakeholders.Keywords
This publication has 14 references indexed in Scilit:
- The Burden of Influenza-Associated Hospitalizations in Oman, January 2008-June 2013PLOS ONE, 2015
- Bacillus Calmette-Guérin (BCG) Vaccine Adverse Events in Victoria, Australia: Analysis of Reports to an Enhanced Passive Surveillance SystemDrug Safety, 2014
- Vaccines against influenza WHO position paper – November 2012.2012
- Variabilidad en la notificación de reacciones adversas a las vacunas de la gripe pandémica y estacional: temporadas 2009-2010 y 2010-2011, Comunitat ValencianaRevista Espanola de Salud Publica, 2012
- Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria.2011
- Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in ChinaThe New England Journal of Medicine, 2011
- Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010Vaccine, 2010
- Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere seasonVaccine, 2010
- Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoringVaccine, 2009
- Adverse drug reactions in elderly patientsBritish Journal of Clinical Pharmacology, 2003